US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1
Patent 11952421 was granted and assigned to Bristol-Myers Squibb Company on April, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 10 Apr, 2024
Golden AI
Edits made to:
Infobox (+39 properties)
Article (+118 characters)
US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1
Article
Patent abstract
The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Anne Freimoser-Grundschober0
Christian Klein0
Ekkehard Moessner0
Joerg Regula0
Klaus Strein0
Michael Molhoj0
Minh Diem Vu0
Oliver Ast0
Pablo Umana0
Ralf Hosse0
Ramona Murr0
Sabine Jung-Imhof0
Samuel Moser0
Stefan Klostermann0
Tanja Fauti0
Wolfgang Schaefer0
Date of Patent
April 9, 2024
0Patent Application Number
155172960
Date Filed
October 8, 2015
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
